Summit Therapeutics plc (SMMT) – Buy Target – $2.75 or better

March 17, 2020

Buy Target – $2.75 or better
Sell Target – TradersPro Sell Signal

Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-571, a preclinical stage candidate to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform.

© Copyright 2020 Investing is Inherently Risky - There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.